Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-04-11 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
董事会决议公告
Report Publication Announcement Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 26th meeting of the 5th Board of Directors of 海思科医药集团股份有限公司. It includes approvals of the 2024 annual general manager's report, 2024 financial report, 2024 annual report and its summary, 2024 board work report, internal control self-evaluation report, and other related matters. The document repeatedly references that the full 2024 annual report and related reports are published separately on the company's designated information disclosure media (巨潮资讯网). The document itself is only 2816 characters, which is relatively short and primarily serves to announce the board meeting resolutions and direct readers to the full annual report elsewhere. This fits the pattern of a Report Publication Announcement (RPA) rather than the full Annual Report (10-K). Therefore, the document is best classified as a Report Publication Announcement (RPA).
2025-04-11 Chinese
华泰联合证券有限责任公司关于海思科医药集团股份有限公司2024年度募集资金存放与实际使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Huatai United Securities regarding the 2024 annual verification of the storage and actual use of raised funds by Hisun Pharmaceutical Group Co., Ltd. It includes specifics about the amount raised, usage, storage, cash management, and compliance with regulatory requirements. The document references regulatory approvals, detailed financial figures related to fundraising, and the use of proceeds. It is not a brief announcement but a comprehensive report on fundraising activities and compliance for the year 2024. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (7,335 characters) and content confirm it is a full report rather than a simple announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-04-11 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company Hai Si Ke Pharmaceutical Group Co., Ltd. It details the nature of the accounting policy changes, references specific accounting standards and regulations issued by the Ministry of Finance, and explains the rationale and impact of the changes. The document includes a board resolution and audit committee review related to the policy change. It is not a full financial report, earnings release, or audit report, but rather a formal announcement of a change in accounting policies approved by the board. The document length is relatively short (2015 characters), and it is a regulatory announcement about accounting policy changes, which fits best under Regulatory Filings (RNS).
2025-04-11 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Deposit and Actual Use of Raised Funds for the Year 2024." It details the amount of funds raised through a non-public stock issuance, the usage of these funds, the balance remaining, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes detailed tables on fund usage, bank accounts, and cash management activities related to the raised capital. It is a specialized report focused on the management and use of capital raised by the company, not a general annual or quarterly financial report. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2025-04-11 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized explanatory statement regarding non-operating fund occupation and other related party fund transactions for the year 2024 by 海思科医药集团股份有限公司. It references the audited financial statements for the year ending December 31, 2024, and includes a summary table of related party transactions. The document is prepared in compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is not a full annual report or interim report but a specific disclosure related to related party transactions and fund occupation, which is typically part of audit or regulatory compliance disclosures. The document is about a specific audit-related disclosure and includes audit firm statements, but it is not a standalone audit report of the entire financial statements. Given the nature of the content focusing on audit-related explanations and compliance with regulatory guidelines on related party transactions, this fits best under Audit Report / Information (AR). The document length is 3044 characters, which is short but contains substantive content beyond a mere announcement or certification, so it is not RPA or RNS. Therefore, the classification is AR with high confidence. FY 2024
2025-04-11 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including total assets, net profit, revenue, earnings per share, and shareholder information. It also discusses the company's business overview, product lines, R&D, marketing, and production models. The length of the document (7510 characters) and the presence of substantive financial data and business analysis indicate this is a summary of the full annual report, not just an announcement or a brief notice. The document is not a certification, proxy, or voting result announcement. Therefore, it fits the definition of an Annual Report (10-K) type filing, specifically an annual report summary which is part of the annual report disclosures. Confidence is high given the detailed financial and operational data presented. FY 2024
2025-04-11 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.